Cargando…

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD

INTRODUCTION: In pivotal trials of patients with autosomal dominant polycystic kidney disease at risk of rapid progression, tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in early-to-moderate (TEMPO 3:4 [NCT00428948]) and moderate- to late-stage (REPRISE [NCT02160145]) chronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallett, Andrew J., Perrone, Ronald D., Rangan, Gopala, Hawley, Carmel, El-Damanawi, Ragada, Hiemstra, Thomas F., Arellano, Carolina Townsend, Lee, Jennifer, Torres, Vicente E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071614/ https://www.ncbi.nlm.nih.gov/pubmed/33912753 http://dx.doi.org/10.1016/j.ekir.2021.01.014

Ejemplares similares

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Cardiovascular Manifestations and Management in ADPKD
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Successful restoration of arteriovenous dialysis access patency after late intervention
por: El-Damanawi, Ragada, et al.
Publicado: (2015)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey
por: El-Damanawi, Ragada, et al.
Publicado: (2017)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
por: Todorova, Polina, et al.
Publicado: (2023)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients
por: Chiha, Joseph, et al.
Publicado: (2012)

Clinical Characteristics of Rapid Progression in Asia-Pacific Patients With ADPKD
por: Oh, Yun Kyu, et al.
Publicado: (2023)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
por: Barnawi, Rashid A, et al.
Publicado: (2018)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study
por: Schirutschke, Holger, et al.
Publicado: (2021)

Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis
por: Sakaida, Isao, et al.
Publicado: (2016)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2023)

A Systematic Review of Reported Outcomes in ADPKD Studies
por: Jdiaa, Sara S., et al.
Publicado: (2022)

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
por: Perrone, Ronald D., et al.
Publicado: (2020)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

DNAJB11-Related Atypical ADPKD in a Kidney Transplant Donor
por: Wilson, Gregory J., et al.
Publicado: (2020)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)
por: Wong, Annette T Y, et al.
Publicado: (2018)

Intrafamilial Variability of ADPKD
por: Lanktree, Matthew B., et al.
Publicado: (2019)

Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD
por: Chedid, Maroun, et al.
Publicado: (2022)

ADPedKD: A Global Online Platform on the Management of Children With ADPKD
por: De Rechter, Stéphanie, et al.
Publicado: (2019)

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
por: Sakaida, Isao, et al.
Publicado: (2015)

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials
por: Gralla, Richard J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r01nem0idp7q38tgeae2838dnc